Raludotatug Deruxtecan

Phase 2Antibody–drug conjugate

Merck & Co.

Raludotatug Deruxtecan is one of 148 biologic programs targeting Intestinal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Ovarian Cancer RecurrentRecruiting

Intestinal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Ovarian Cancer RecurrentPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Raludotatug Deruxtecan

Merck & Co.

Phase 2

4 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Vizimpro

Pfizer

Preclinical

4 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Advanced/metastatic Solid Tumors

NCT06660654

Q1 2029

Phase 2Active, not recruiting

Intestinal Cancer

NCT06864169

PreclinicalRecruiting

Ovarian Cancer Recurrent

NCT06843447

Q1 2032

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780085

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT06660654·200 enrolled

Intestinal Cancer1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06864169·160 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·460 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780085·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Raludotatug Deruxtecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raludotatug Deruxtecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raludotatug Deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Raludotatug Deruxtecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Q1 2032

Trials by Indication[1]

Advanced/Metastatic Solid Tumors1 trial

Intestinal Cancer1 trial

Ovarian Cancer Recurrent1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News